New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant ...
This week, Hach has revived the story to taunt LiPetri, who of the two is considered the insider in the Nassau County GOP ...
Donald Trump appointed Jeff Gunter ambassador to Iceland in 2018, and Gunter served in the post until 2021. Since then, Trump ...
Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System Atrophy ...
In April 2026, Context received Human Research Ethics Committee (“HREC”) approval and Clinical Trial Notification (“CTN”) acknowledgement by the Australian Therapeutic Goods Administration (“TGA”) to ...
RAINIER is a multicenter, open-label, multi-cohort phase 1b/2 dose-optimization study enrolling adults aged 18 years or older ...
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a ...
UCB has agreed to acquire Candid Therapeutics for up-to-$2.2 billion, in a deal designed to expand the buyer’s presence in ...
UCB will pay up to $2.2bn for Candid Therapeutics, betting on cizutamig and the wider T-cell engager rush in autoimmune disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results